Biodesix, Inc.

Integrated Diagnostics, Inc.

Indi Molecular, Inc.

Sera Prognostics, Inc.

Paul Edward Kearney

Xiao-Jun Li

Clive Hayward

Kenneth Charles Fang

Tracey Cristine Fleischer

John Jay Boniface

Ashoka Dharmapriya Polpitiya

Durlin Edward Hickok

Gregory Charles Critchfield

Andrew Gassman

Jeff Flick

Chad Bradford

James R Heath

Heather Dawn Agnew

Arundhati Nag

Samir Das

Rosemary Dyane Rohde

Suresh Mark Pitram

Steven Wesley Millward

Kaycie Deyle

Miguel Dominguez Geeraerts

Tsun Yin Lai

Douglas Spicer

Stephen W Hunsucker

Lik Wee Lee

Scott Law

Julja Burchard

Ashoka Polpitiya

Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).

Compositions, methods and kits for diagnosis of lung cancer

The disclosure provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. Also provided is a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 to determine the probability for preterm birth in the pregnant female.

Biomarker pairs for predicting preterm birth

Compositions and methods for predicting due date and time to birth for a pregnancy with significantly higher accuracy than current clinical methods. The compositions and methods for predicting due date and time to birth for a pregnancy can also identify those pregnancies that will deliver earlier than the due date derived from Last Menstrual Period (LMP) and/or obstetric ultrasonography (US) dating.

Pregnancy clock proteins for predicting due date and time to birth

Provided herein are methods for developing selected reaction monitoring mass spectrometry (LC-SRM-MS) assays.

SRM methods in Alzheimer's disease and neurological disease assays

The present invention provides methods for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. The present invention also provides compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).

Selected reaction monitoring assays

The present application provides stable peptide-based Akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including Akt capture agents, using iterative on-bead in situ click chemistry.

Akt-specific capture agents, compositions, and methods of using and making

Methods are provided for determining the expression level of target proteins in a subject. A plurality of respective peptide transitions are generated from a plurality of proteins obtained from a biological sample from the subject, wherein the plurality of proteins comprises both target and normalizing proteins. A mass spectroscopy (MS) signal intensity is measured from the plurality of respective peptide transitions and a plurality of corresponding stable isotope-labeled internal standard (SIS) peptide transitions. For each of the plurality of proteins, a response ratio is calculated between the MS signal intensity of the respective peptide transition and the corresponding SIS peptide transition. The response ratio for each target protein is normalized by a sample-dependent normalization factor calculated from the response ratio for each normalizing protein, wherein the normalized response ratios provide a determination of the expression level of the target proteins.

Integrated quantification method for protein measurements in clinical proteomics

Disclosed herein are novel diagnostic lung cancer panels and the use of these panels to diagnose, predict, and characterize lung cancer and to monitor or predict treatment efficacy.

Diagnostic lung cancer panel and methods for its use

Growing community of inventors

Seattle, WA, United States of America

Paul Edward Kearney